Cancer discoveryHumansPPAR gammaAntineoplastic Agents
First-of-Its-Kind PPARG Inhibitor Shows Compelling Activity.
Published: 202610.1158/2159-8290.CD-NW2025-0103
Abstract
A novel inhibitor of the protein PPARG, which is overexpressed in most cases of advanced urothelial carcinoma, led to tumor shrinkage in most patients with high PPARG expression who received the drug FX-909. In addition, some responding patients had…
Preview only. Read the full abstract at the source